Prevenar vaccination: review of the global data, 2006.

@article{Center2007PrevenarVR,
  title={Prevenar vaccination: review of the global data, 2006.},
  author={Kimberly J Center},
  journal={Vaccine},
  year={2007},
  volume={25 16},
  pages={3085-9}
}
The 7-valent pneumococcal conjugate vaccine, Prevenar, was first licensed in the United States in 2000 for the prevention of invasive pneumococcal disease (IPD) caused by the serotypes included in the vaccine. It is presently approved in more than 70 countries, and more than 100 million doses of vaccine have been distributed to date. Within 1 year of routine use in the US, incidence of vaccine-serotype IPD had fallen dramatically among children younger than 2 years, with indirect effects noted… CONTINUE READING